Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16394 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yuichiro Yano und 9 weiteren Autor:innen. Beteiligte Einrichtung: NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To describe temporal changes in the characteristics of medication‐initiator cohorts in persons with chronic kidney disease (CKD) and type 2 diabetes (T2D). Materials and Methods Adults with CKD and T2D initiating sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i) or glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) were identified in the Japan Chronic Kidney Disease Database Extension in each of the two study periods (Period I: 1 January 2014–30 June 2021; Period II: 1 July 2021–31 December 2022). For each cohort, baseline characteristics and the standard mean differences (SMD) between periods I and II were assessed.
Results
During study periods I and II, 1157 and 1122 SGLT‐2i, and 329 and 369 GLP‐1RA new users were identified, respectively. All four cohorts had similar age, sex and comorbidity patterns, with a mean age spanning 66.1–69.5 years and 60%–70% being male. More than 80% of persons had hypertension and 60% had congestive heart failure. In the SGLT‐2i cohorts, we observed a decrease in prior metformin and dipeptidyl peptidase‐4 inhibitor use (SMD ≥0.5 and 0.8). In the GLP‐1RA cohorts, there was a medium decrease in persons using insulin.
Conclusions
With the introduction of new treatments and emerging evidence supporting cardio‐renal protective effects in people with CKD and T2D, notable changes in baseline treatment were observed in the medication‐initiator cohort characteristics. These findings suggest the earlier use of cardio‐renal protective medications in the course of T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan.
- Department of General Medicine, Faculty of Medicine, Juntendo University, Tokyo, Japan.
- AI Incubation Farm, Juntendo University, Tokyo, Japan.
- Medical Affairs and Pharmacovigilance, Bayer Yakuhin Ltd, Osaka, Japan.
- Genki Plaza Medical Centre for Health Care, Tokyo, Japan.
- Integrated Evidence Generation and Business Innovation, Bayer AG, Berlin, Germany.
ORCID-Profile: Suguru Okami
Förderung
- Bayer
Zitieren
APA
Yano, Y., Okami, S., Kanegae, H., Oberprieler, N. G., Johannes, C., Yamashita, S., Yoshikawa-Ryan, K., Kovesdy, C. P., Vizcaya, D., & Kashihara, N. (2025). Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16394
Vancouver
Yano Y, Okami S, Kanegae H, Oberprieler NG, Johannes C, Yamashita S, et al. Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16394
BibTeX
@article{Yano2025,
author = {Yano, Yuichiro and Okami, Suguru and Kanegae, Hiroshi and Oberprieler, Nikolaus G and Johannes, Catherine and Yamashita, Satoshi and Yoshikawa-Ryan, Kanae and Kovesdy, Csaba P and Vizcaya, David and Kashihara, Naoki},
title = {Transitional changes in medication‐initiator cohort profiles in persons with chronic kidney disease and type 2 diabetes—A hospital‐based cohort study in Japan},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16394}
}
EUVIMED